Ionis (IONS) - Revenue and Sales Volume

Ionis Pharmaceuticals (IONS) dictates premium pricing for orphan drugs thanks to its unique RNA technology, although cash flows remain volatile due to one-off partner payments. The company's sales metrics help distinguish this chaos from the underlying trend, where the value of 0.96 reflects this status. Primary threats are concentrated in the high cost of clinical trials and potential failures during the final stages of development.

Ionis Pharmaceuticals (IONS) - Company Revenue from 07/04/2022 to 11/14/2026

Comprehensive metric breakdowns and analytics for Isis Pharmaceuticals (IONS)

- share price and expert price forecast:

Price Performance Chart Ionis Pharmaceuticals|IONS - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Ionis Pharma|IONS - Total Company Value

- company book value details:

Accounting Value of a Share Ionis|IONS - Company Book Value|Market Cap to Net Assets Ratio ionispharma.com|IONS - Company Total Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

IONS - Net Profit|Company Profit Forecast Ionis Pharmaceuticals|IONS - P/E Multiple|Projected Price to Earnings Ionis|IONS - PEG Multiple|EV/EBITDA Multiple Ionis Pharma|IONS - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Ionis|IONS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months ionispharma.com|IONS - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Ionis Pharmaceuticals

- sales volume and revenue indicators:

IONS - Company Revenue|Company Expected Sales Volume ionispharma.com|IONS - Price-to-Revenue Ratio|Market Cap to Projected Revenue Ionis Pharma

Summary company analysis:IONS (Ionis)

Fundamental asset screening requires separating short-term noise from the actual business value. This indicator captures the daily volume of actual cash inflows from product sales. By analyzing the sales volatility of the company, an investor can identify seasonal anomalies and the true revenue growth rate. For Ionis Pharmaceuticals (IONS), this flow is generated by the sale of unique RNA therapies. Regular licensing royalties from strategic partners also exert a significant influence on the dynamics.

Competing companies